Gene Therapy Shows Promise in Treating Severe β-Thalassemia

Gene Therapy Demonstrates High Efficacy in Severe β-Thalassemia

A phase 3 trial has highlighted betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia. This breakthrough offers hope for patients suffering from this debilitating condition, suggesting a significant advancement in the treatment landscape.

New Evidence Highlights Stability of Lentiviral Gene Therapies

In related research, scientists have studied the long-term safety of lentiviral gene therapy in primates. The findings are promising, showing no evidence of somatic mutations or malignancy, which underscores the potential safety and stability of these therapies for future clinical applications.